Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance

Digestive Diseases and Sciences

Volumn 61, Issue 1, 2016, Pages 149-157

  Qiu, Xueping ^a   Hu, Bo ^b   Huang, Yifang ^a   Deng, Yunte ^c   Wang, Xuebin ^a   Zheng, Fang ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c HUBEI CANCER HOSPITAL   (China)

Author keywords

ACP1; BMP4; DNA methylation; Hepatocellular carcinoma; TSPYL5

Indexed keywords

ACP1 PROTEIN, HUMAN; BMP4 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 4; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE PHOSPHATASE; TSPYL5 PROTEIN, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TIME FACTOR;

AREA UNDER CURVE; BIOMARKERS, TUMOR; BONE MORPHOGENETIC PROTEIN 4; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS; RISK FACTORS; ROC CURVE; TIME FACTORS;

EID: 84952990273     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3878-3     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.e1.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
4. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–328.
5. Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11:340–349.
6. Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014;5:673–691.
7. Um TH, Kim H, Oh BK, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 2011;54:939–947.
8. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908–918.
9. Mah WC, Lee CG. DNA methylation: potential biomarker in hepatocellular carcinoma. Biomark Res. 2014;2:5.
10. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn. 2012;12:473–487.
11. Villanueva A, Portela A, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61:1945–1956.
12. Alho I, Costa L, Bicho M, Coelho C. The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis. Tumour Biol. 2013;34:1979–1989.
13. Ricketts CJ, Morris MR, Gentle D, et al. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics. 2012;7:278–290.
14. Olk-Batz C, Poetsch AR, Nollke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011;117:4871–4880.
15. Hsu YT, Gu F, Huang YW, et al. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013;19:6272–6285.
16. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013;8:e55761.
17. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006;66:7490–7501.
18. Jung Y, Park J, Bang YJ, Kim TY. Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Invest. 2008;88:153–160.
19. Oka D, Yamashita S, Tomioka T, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer. 2009;115:3412–3426.
20. Kim EJ, Lee SY, Kim TR, et al. TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21(WAF1/Cip1) and PTEN/AKT pathway. Biochem Biophys Res Commun. 2010;392:448–453.
21. Shen J, LeFave C, Sirosh I, Siegel AB, Tycko B, Santella RM. Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas. BMC Med Genomics. 2015;8:28.
22. Shen J, Wang S, Zhang YJ, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 2012;55:1799–1808.
23. Ng EK, Leung CP, Shin VY, et al. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One. 2011;6:e22233.
24. Hua D, Hu Y, Wu YY, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:455–460.
25. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One. 2012;7:e37928.
26. Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res. 2010;692:26–33.
27. Jain S, Chen S, Chang KC, et al. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One. 2012;7:e35789.
28. Lou C, Du Z, Yang B, Gao Y, Wang Y, Fang S. Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci. 2009;100:996–1004.
29. Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci. 2014;105:749–754.
30. Ramachandran K, Singal R. DNA methylation and field cancerization. Epigenomics. 2012;4:243–245.
31. Cheng Y, Zhang C, Zhao J, et al. Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma. Exp Mol Pathol. 2010;88:112–117.
32. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–510.
33. Lu X, Zhao H, Yang H, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2009;100:488–493.
34. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
35. Yang T, Lin C, Zhai J, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona clinic liver cancer (BCLC) staging. J Cancer Res Clin Oncol. 2012;138:1121–1129.